Patent intelligence · US
US 7482489
Enantiomerically pure (R)-albuterol dibenzoyltartrate and protected analogs thereof
Enantiomerically pure (R)-albuterol dibenzoyltartrate and protected analogs thereof
Patent details — US 7482489
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 27, 2009
- Expiration
- Jan 22, 2029
- Claims
- 2
- CPC classes
- A61P, A61P11/00, A61P11/06, A61P11/08
Quick answer
US 7482489 (Enantiomerically pure (R)-albuterol dibenzoyltartrate and protected analogs thereof) is held by Teva Pharmaceutical Fine Chemicals S.R.L.. Status: granted. Granted Jan 27, 2009. Expires Jan 22, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 2
- CPC classes
- A61P, A61P11/00, A61P11/06, A61P11/08, A61P43/00
More from Teva Pharmaceutical Fine Chemicals S.R.L.
Related pharmaceutical patents in our USPTO index.
-
US 12310929
Use of rasagiline for the treatment of restless legs syndrome
granted -
US 12258401
Anti-CD47 combination therapy
granted -
US 12157729
Solid state forms of Belumosudil and Belumosudil salts
granted -
US 12139528
Treating refractory migraine
granted -
US 12091388
Solid state forms of Reproxalap
granted -
US 11826322
Pre-filled syringe
granted -
US 11813359
Sustained release olanzapine formulations
granted -
US 11773083
Solid state forms of Belumosudil and Belumosudil salts
granted
Frequently asked questions
What is US patent 7482489?
US 7482489 (Enantiomerically pure (R)-albuterol dibenzoyltartrate and protected analogs thereof) is held by Teva Pharmaceutical Fine Chemicals S.R.L.. Status: granted. Granted Jan 27, 2009. Expires Jan 22, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7482489?
Teva Pharmaceutical Fine Chemicals S.R.L. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 454 pharmaceutical patents for this assignee.
When does US 7482489 expire?
Our index shows an expiration date of Jan 22, 2029 (3 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.